NTCELL: Adisease-modifying celltherapyfor Parkinson's disease
Dr Belinda Di Bartolo
Chief Operating Officer
22 J U N E 2022
Disclaimer
This document contains certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward- looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar
expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates.
Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements.
There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements
regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales.
In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects.
Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.
LCT is providing this information as of the date of this presentation and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.
lctglobal.com | ASX:LCT | OTCQB:LVCLY | 2 |
LCT at a glance
Mission and Vision
Discovering, developing and commercialising novel treatments for debilitating conditions.
Diabetes: DIABECELL
Initially developed by LCT now being further developed by
Otsuka Pharmaceutical Factory in the U.S.
Parkinson's Disease: NTCELL
A disease modifying cell therapy for Parkinson's Disease
lctglobal.com | ASX:LCT | OTCQB:LVCLY | 3 |
lctglobal.com | ASX:LCT | OTCQB:LVCLY | 4 |
Experienced Leadership
lctglobal.com | ASX:LCT | OTCQB:LVCLY | 5 |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Living Cell Technologies Limited published this content on 22 June 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 June 2022 12:24:02 UTC.